About Betagenon

We are a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders diseases in metabolically challenged elderly and/or obese individuals. Drugs that activate AMPK are expected to have beneficial effects on metabolic and cardiovascular diseases and on certain cancers.


Betagenon is financed by private investors, the foundation Stiftelsen J.C. Kempes Minne, www.kempe.com, and Balticgruppen AB, www.balticgruppen.se.